Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Yared Hailemichael(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Jared K. Burks(The University of Texas MD Anderson Cancer Center), Sang T. Kim(Yale University), Wai Chin Foo(The University of Texas MD Anderson Cancer Center), Salah-Eddine Bentebibel(The University of Texas MD Anderson Cancer Center), Muhammad O. Awiwi(Rutgers, The State University of New Jersey), Jonathan L. Curry(The University of Texas MD Anderson Cancer Center), Cassian Yee(The University of Texas MD Anderson Cancer Center), Chrystia M. Zobniw(The University of Texas MD Anderson Cancer Center), Khalida Wani(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Antony Mathew(The University of Texas MD Anderson Cancer Center), Brenda Melendez(The University of Texas MD Anderson Cancer Center), James P. Allison(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Gregory Lizée(The University of Texas MD Anderson Cancer Center), Chantal Saberian(The University of Texas MD Anderson Cancer Center), Faisal Fa’ak(New York University), Sühendan Ekmekçioglu(The University of Texas MD Anderson Cancer Center), Khaled M. Elsayes(The University of Texas MD Anderson Cancer Center), Christine Spillson(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Dai Ogata(Unknown), Padmanee Sharma(The University of Texas MD Anderson Cancer Center), Roza Nurieva(The University of Texas MD Anderson Cancer Center), Luisa M. Solis Soto(The University of Texas MD Anderson Cancer Center), Adewunmi Falohun(The University of Texas MD Anderson Cancer Center), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Daniel H. Johnson(The University of Texas MD Anderson Cancer Center), Shalini Singh(The University of Texas MD Anderson Cancer Center), Noha Abdel‐Wahab(The University of Texas MD Anderson Cancer Center), Van Trinh(The University of Texas MD Anderson Cancer Center), Hamzah Abu‐Sbeih(The University of Texas MD Anderson Cancer Center)
Cited by 338
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k